CASI Pharmaceuticals Shares Are Trading Higher After the Company Announced Plans to Submit an Investigational New Drug Application to the FDA for CID-103 for the Treatment of Antibody-mediated Rejection in Kidney Transplant Recipients. Also, the...
CASI Pharmaceuticals Shares Are Trading Higher After the Company Announced Plans to Submit an Investigational New Drug Application to the FDA for CID-103 for the Treatment of Antibody-mediated Rejection in Kidney Transplant Recipients. Also, the...
casi製藥股價上漲，公司宣佈計劃向FDA提交CID-103用於治療腎移植接受者的抗體介導性排斥反應的新藥申請。此外，該公司還將提交新藥延長釋放替諾福韋的新藥申請以供臨床前評估。
CASI Pharmaceuticals Shares Are Trading Higher After the Company Announced Plans to Submit an Investigational New Drug Application to the FDA for CID-103 for the Treatment of Antibody-mediated Rejection in Kidney Transplant Recipients. Also, the Company Received a Preliminary Non-binding Proposal Letter From CEO and Chairman Wei-Wu He to Acquire Its Business Operations in China.
casi製藥股票上漲，公司宣佈計劃向FDA提交CID-103的新藥申請，用於治療抗體介導的腎移植排斥。此外，該公司收到了董事長賀衛午的初步非約束性提議信，以收購其在中國的業務經營。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。